Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer

Identification of Molecular and Epidemiological Risk Factors in the Development of Gastric Cancer in High-risk Predominantly Hispanic Population

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

This protocol is a single-institution feasibility study to identify the molecular and epidemiological risk factors in the development of gastric cancer in high-risk predominantly Hispanic South Texas population. The study is broken down into two main parts: 1) To identify molecular differences in gastric adenocarcinoma (GAC) between Non-Hispanics and Hispanics, stratified by age, and in benign, pre-malignant, and malignant gastric lesions; and 2) To identify environmental and clinicopathological factors in Hispanics associated with specific molecular changes linked to the development of GAC.

Who May Be Eligible (Plain English)

Who May Qualify: - Aged 18 years or older - Patient with diagnosed by tissue sample (biopsy-confirmed) diagnosis of gastric adenocarcinoma - Able to understand English or Spanish (only for the prospective cohort) - GEJ adenocarcinoma Type II (within 1 cm above and 2 cm below the GEJ) and Type III (2-5 cm below the GEJ) - Hyperplastic polyps Who Should NOT Join This Trial: - Clinically AND genetically confirmed diagnosis of well-established hereditary cancer syndrome - Gastroesophageal junction (GEJ) adenocarcinoma Type I (1-5 cm above the GEJ) as they are treated as esophageal cancer - Other benign or malignant histology types (i.e. leiomyoma, gastrointestinal stroma tumors, fundic gland polyps, etc.) Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Aged 18 years or older * Patient with histologically confirmed diagnosis of gastric adenocarcinoma * Able to understand English or Spanish (only for the prospective cohort) * GEJ adenocarcinoma Type II (within 1 cm above and 2 cm below the GEJ) and Type III (2-5 cm below the GEJ) * Hyperplastic polyps Exclusion Criteria: * Clinically AND genetically confirmed diagnosis of well-established hereditary cancer syndrome * Gastroesophageal junction (GEJ) adenocarcinoma Type I (1-5 cm above the GEJ) as they are treated as esophageal cancer * Other benign or malignant histology types (i.e. leiomyoma, gastrointestinal stroma tumors, fundic gland polyps, etc.)

Treatments Being Tested

OTHER

Molecular testing for all participants.

Molecular testing on formalin fixed paraffin-embedded (FFPE) tissues on retrospectively identified patients with gastric adenocarcinoma.

OTHER

Germline Testing

Germline testing will be done on prospectively identified patients and in retrospectively identified patients who are still alive.

OTHER

Survey

Survey will be administered on prospectively identified patients and in retrospectively identified patients who are still alive. Survey will be administered in person or via telephone. The survey in the language of the participants choice (English or Spanish) on sociodemographic information, current and/or prior PPI (proton pump inhibitor), H2 blocker, antibiotic, tobacco, alcohol, and recreational drug use. Questionnaire will include other risk factors for gastric adenocarcinoma such as certain dietary constituents (high salt diet, high consumption of processed meat, etc.) and occupational exposures.

Locations (1)

Mays Cancer Center, UT Health San Antonio
San Antonio, Texas, United States